Dichotomous outcomes | Continuous outcomes | All studies | ||||
---|---|---|---|---|---|---|
Number | (%) | Number | (%) | Number | (%) | |
n = 13 | n = 15 | n = 28 | ||||
Results – any type* | 4 | (30.8) | 4 | (26.7) | 8 | (28.6) |
Focus on statistically significant results from: | ||||||
Within-group analyses | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
Subgroups | 4 | (30.8) | 3 | (20.0) | 7 | (25.0) |
Secondary outcomes | 0 | (0.0) | 3 | (20.0) | 3 | (10.7) |
Per protocol analysis | 2 | (15.4) | 1 | (6.7) | 3 | (10.7) |
Other | 1 | (7.7) | 0 | (0.0) | 1 | (3.6) |
Discussion – any type | 8 | (61.5) | 8 | (53.3) | 16 | (57.1) |
Focus on statistically significant results from: | ||||||
Within-group analyses | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
Subgroups | 4 | (30.8) | 4 | (26.7) | 8 | (28.6) |
Secondary outcomes | 0 | (0.0) | 5 | (33.3) | 5 | (17.9) |
Per protocol analysis | 2 | (15.4) | 1 | (6.7) | 3 | (10.7) |
Claims equivalence | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
Rules out adverse effect | 1 | (7.7) | 5 | (33.3) | 6 | (21.4) |
Other | 5 | (38.5) | 0 | (0.0) | 5 | (17.9) |
Conclusions – any type | 7 | (53.8) | 10 | (66.6) | 17 | (60.7) |
Claims effectiveness with no acknowledgement of NS results for primary outcome | 4 | (30.8) | 4 | (26.7) | 8 | (28.6) |
Claims equivalence | 1 | (7.7) | 5 | (33.3) | 6 | (21.4) |
Rules out adverse effect | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
Acknowledges non-significance, but emphasizes significant results for other outcomes | 3 | (23.1) | 4 | (26.7) | 7 | (25.0) |
Acknowledges non-significance, but emphasizes treatment benefit | 2 | (15.4) | 3 | (20.0) | 5 | (17.9) |
Emphasizes benefit based on new outcome | 1 | (7.7) | 3 | (20.0 | 4 | (14.3) |
Other | 0 | (0.0) | 0 | (0.0) | 2 | (7.1) |